Cargando…

Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models

BACKGROUND: The upregulation of antioxidant mechanisms is a common occurrence in cancer cells, as they strive to maintain balanced redox state and prevent oxidative damage. This includes the upregulation of the cystine/glutamate antiporter xCT, which plays a crucial role in protecting cancer cells f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiu, Roberto, Cossu, Chiara, Iacoviello, Antonella, Conti, Laura, Bolli, Elisabetta, Ponzone, Luca, Magri, Jolanda, Rumandla, Alekya, Calautti, Enzo, Cavallo, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540318/ https://www.ncbi.nlm.nih.gov/pubmed/37770957 http://dx.doi.org/10.1186/s13046-023-02830-x

Ejemplares similares

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
por: Magri, Jolanda, et al.
Publicado: (2021)

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017)

Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017)

Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019)

The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022)

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019)

Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
por: Lim, Jonathan K. M., et al.
Publicado: (2019)

Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells (GSCs)
por: Koch, Katharina, et al.
Publicado: (2021)

Increased expression of cystine/glutamate antiporter in multiple sclerosis
por: Pampliega, Olatz, et al.
Publicado: (2011)

Change of cystine/glutamate antiporter expression in ethanol-dependent rats
por: Peana, Alessandra T., et al.
Publicado: (2014)

Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues
por: Martis, Renita M., et al.
Publicado: (2020)

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
por: Rolih, Valeria, et al.
Publicado: (2020)

The System xc- Cystine/Glutamate Antiporter: An Exciting Target for Antiepileptogenic Therapy?
por: Gallagher, Martin
Publicado: (2020)

Rotavirus-induced lncRNA SLC7A11-AS1 promotes ferroptosis by targeting cystine/glutamate antiporter xCT (SLC7A11) to facilitate virus infection
por: Banerjee, Shreya, et al.
Publicado: (2023)

Corticostriatal dysfunction and social interaction deficits in mice lacking the cystine/glutamate antiporter
por: Bentea, Eduard, et al.
Publicado: (2020)

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
por: Hung, Chung-Chieh, et al.
Publicado: (2021)

Molecular basis for redox control by the human cystine/glutamate antiporter system xc(−)
por: Parker, Joanne L., et al.
Publicado: (2021)

Early Onset of Age-Related Cataracts in Cystine/Glutamate Antiporter Knockout Mice
por: Martis, Renita Maria, et al.
Publicado: (2021)

High-Throughput Assay Development for Cystine-Glutamate Antiporter (x(c) (-)) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells
por: Thomas, Ajit G., et al.
Publicado: (2015)

Cystine/glutamate antiporter System x(c)(-) deficiency impairs insulin secretion in mice
por: de Baat, Axel, et al.
Publicado: (2023)

Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma
por: Dai, Lu, et al.
Publicado: (2014)

Structure‐Activity‐Relationship‐Aided Design and Synthesis of xCT Antiporter Inhibitors
por: Cirillo, Davide, et al.
Publicado: (2021)

Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission
por: Fukuyama, Kouji, et al.
Publicado: (2018)

Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: Evidence of ferroptosis
por: Ashraf, Azhaar, et al.
Publicado: (2020)

Cystine/Glutamate antiporter system x(c)(-) deficiency impairs macrophage glutathione metabolism and cytokine production
por: de Baat, Axel, et al.
Publicado: (2023)

The cystine/glutamate antiporter system x(c)(−) drives breast tumor cell glutamate release and cancer-induced bone pain
por: Slosky, Lauren M., et al.
Publicado: (2016)

The x(c)(−) cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
por: Lo, M, et al.
Publicado: (2008)

Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease
por: Vallerga, Costanza L., et al.
Publicado: (2020)

Cystine–glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice
por: Sprimont, Lindsay, et al.
Publicado: (2021)

Molecular cloning, tissue distribution and the expression of cystine/glutamate exchanger (xCT, SLC7A11) in different tissues during development in broiler chickens
por: Choi, Janghan, et al.
Publicado: (2020)

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
por: Bolli, Elisabetta, et al.
Publicado: (2017)

[(18)F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis
por: Hoehne, Aileen, et al.
Publicado: (2018)

The Cystine/Glutamate Antiporter, System x(c)(–), Contributes to Cortical Infarction After Moderate but Not Severe Focal Cerebral Ischemia in Mice
por: He, Yan, et al.
Publicado: (2022)

Structural investigation of human cystine/glutamate antiporter system x(c) (−) (Sx(c) (−)) using homology modeling and molecular dynamics
por: Hang, Tran Dieu, et al.
Publicado: (2022)

Yokukansan, a Kampo Medicine, Protects PC12 Cells from Glutamate-Induced Death by Augmenting Gene Expression of Cystine/Glutamate Antiporter System Xc(−)
por: Kanno, Hitomi, et al.
Publicado: (2014)

A Cystine-Cysteine Intercellular Shuttle Prevents Ferroptosis in xCT(KO) Pancreatic Ductal Adenocarcinoma Cells
por: Meira, Willian, et al.
Publicado: (2021)

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
por: Koppula, Pranavi, et al.
Publicado: (2020)

Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma
por: Nagane, Masaki, et al.
Publicado: (2018)

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
por: Hasegawa, Masanori, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_unt9qrssapjtrshjolb50h5ph0